卵巢被單一覆蓋層的表層上皮細(xì)胞所覆蓋，這層細(xì)胞在體內(nèi)的形態(tài)由鱗狀上皮變化成低柱狀立方形。OSEpiC參與周期性排卵卵泡破裂和隨后的修復(fù)。OSEpiC表達(dá)大量的多肽類激素，性激素，生長因子和受體。這些眾多的生物物質(zhì)與卵巢上皮癌和性傳播疾病的發(fā)生發(fā)展有關(guān)。研究相應(yīng)細(xì)胞通路的畸變可以了解OSEpiC的生長、凋亡、轉(zhuǎn)化和在疾病發(fā)生時的功能及潛在的標(biāo)記物質(zhì)，這些可以為臨床治療疾病提供非常重要的信息。
Sciencell研究實(shí)驗(yàn)室的HOSEC是從人卵巢分離得到的，原代凍存，冰凍運(yùn)輸。每管細(xì)胞密度超過5×10^5/ml。細(xì)胞特性經(jīng)cytokeratine-14, -18, and -19免疫熒光鑒定。本細(xì)胞經(jīng)檢測不含HIV-1、HBV、HCV、支原體、細(xì)菌、酵母菌和真菌。如采用ScienCell?實(shí)驗(yàn)室特制的培養(yǎng)基，可保證此細(xì)胞5倍增增殖。
推薦培養(yǎng)基：卵巢上皮細(xì)胞培養(yǎng)基?(OEpiCM, Cat. #7311)
|
貨號
|
7310
|
|
產(chǎn)地
|
美國
|
|
縮寫
|
HOSEpiC
|
|
規(guī)格
|
5 x 10^5 /1ml
|
|
用途
|
科研
|
|
儲存
|
液氮
|
|
運(yùn)輸
|
干冰
|
|
關(guān)鍵字
|
人卵巢表層上皮細(xì)胞 HOSEpiC 人卵巢表層上皮細(xì)胞 HOSEpiC 人卵巢表層上皮細(xì)胞 HOSEpiC 人卵巢表層上皮細(xì)胞 HOSEpiC 人卵巢表層上皮細(xì)胞 HOSEpiC 人卵巢表層上皮細(xì)胞 HOSEpiC 人卵巢表層上皮細(xì)胞 HOSEpiC 人卵巢表層上皮細(xì)胞 HOSEpiC
|
公司簡介
|
合肥星肽生物科技有限公司作為專業(yè)的ScienCell中國代理商，專業(yè)經(jīng)營實(shí)驗(yàn)室科研用原代細(xì)胞、原代細(xì)胞專用培養(yǎng)基、原代細(xì)胞無血清培養(yǎng)基、干細(xì)胞、干細(xì)胞培養(yǎng)基、干細(xì)胞無血清培養(yǎng)基的研究和開發(fā)。合肥星肽生物科技有限公司始終致力于為客戶提供可靠的研究材料以及方便快捷的服務(wù)，對購買項(xiàng)目的前期資料提供,中期合同保證,后期貨物跟蹤到 *終售后的確保項(xiàng)目準(zhǔn)確到位，都有相關(guān)專業(yè)人士進(jìn)行維護(hù),確保您在合肥合肥星肽生物科技有限公司公司獲得*上等服務(wù)！
|
|
聯(lián)系方式
|
何經(jīng)理，合肥星肽生物科技有限公司，Tel：0551-63802898 400-8702-898，
E-mail：info@qingbio.com http://mails.js65k.cn QQ:514713116
|
1.) Takahashi Y, Koyanagi T, Suzuki Y, Saga Y, Kanomata N, Moriya T, Suzuki M, Sato Y. (2012) "Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis."?Mol Cancer Res. 10: 1135-46.
2.) Semaan A, Qazi AM, Seward S, Chamala S, Bryant CS, Kumar S, Morris R, Steffes CP, Bouwman DL, Mukarah AR, Weaver DW, Gruber SA, Batchu RB. (2011) "MicroRNA-101 Inhibits Growth of Epithelial Ovarian Cancer by Relieving Chromatin-Mediated Transcriptional Repression of p21waf1/cip1."?Pharm Res. 28: 3079-90.
3.) Guo AM, Liu X, Al-Wahab Z, Maddippati KR, Ali-Fehmi R, Scicli AG, Munkarah AR. (2011) "Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival."?Cancer ChemotherPharmacol.68: 1273-83.
4.) Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, K?lai T, Hideg K, Kuppusamy P. (2010) "Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells."?Free Radic Biol Med. 48: 1228-35.?
5.) Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, Trigg NJ, Rivera BK, K?lai T, Hideg K, Kuppusamy P. (2010) "Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts."?Mol Cancer Ther. 9: 1169-79.
6.) Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, Kalai T, Hideg K, Kuppusamy P. (2010) "Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenylpiperidones: differential cytotoxicity in healthy and cancer cells."?Free RadicBiol Med.48: 1228-35.
?
There are no product questions yet.
